Fig. 2: Process design parameters for FTR-LNP formulation optimization.
From: Development of an extended action fostemsavir lipid nanoparticle
a Size and PDI of different FTR-LNP formulations developed by microfluidics by changing FRR; LNP1, LNP2, LNP3, LNP4 and LNP5 have FRR of 1:1, 1.5:1, 2:2, 3:1 and 4:1, respectively. b Zeta potential of different FTR-LNP formulations at pH 7.0. c, d Stability of LNP formulations up to 30 days based on size and PDI measurements. e Zeta potential of LNP1 up to 30 days at two different pH, citrate buffer (pH 3.0) and phosphate-buffered saline (PBS; pH 7.4). f Comparison of size distributions of five FTR-LNP formulations prepared by variable FRRs. Data is presented as mean + SEM.
